Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Handok Inc. is a prominent player in the pharmaceutical industry, engaged in the development, production, and distribution of a wide range of pharmaceutical products. With its core operations centered in South Korea, Handok Inc. focuses on delivering innovative healthcare solutions that encompass prescription drugs, over-the-counter medicines, and medical devices. The company's diverse product portfolio spans therapeutic areas such as cardiovascular diseases, diabetes, vaccines, and various chronic conditions. Handok Inc. has established itself as a critical component of the healthcare sector, consistently investing in research and development to introduce advanced pharmaceuticals that cater to evolving patient needs and medical standards. The company partners with global and regional firms, leveraging strategic alliances to enhance its market reach and technological capabilities. As a publicly traded company, Handok Inc. plays an essential role in South Korea's healthcare landscape, contributing significantly to the country's pharmaceutical exports and healthcare innovation. Its commitment to quality and efficacy underscores its reputation as a trusted provider of essential healthcare solutions across domestic and international markets.
₩7,410.00
+₩90.00 (+1.23%)
Live · 11:09 AM
Operating margin is thin at 0.62%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 5.5%, steady but not accelerating.
Negative free cash flow of -₩11.86B. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩550.69B
▲ +5.5% YoY
Net Income (TTM)
-₩3.10B
▲ +95.8% YoY
Op. Margin
1.03%
▲ +0.5pp YoY
ROIC
0.39%
▲ +0.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-₩10.84B
▲ +46.6% YoY
Op. Cash Flow (TTM)
₩13.16B
▲ +124.9% YoY
Net Debt
₩350.51B
Cash & Equiv.
₩28.07B
3Y CAGR: -0.5%
Continue Research
Handok (002390.XKRX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in .
On quality, Handok scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 2.8%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Handok scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 1.0% operating margin and a 0.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Handok pays a regular dividend of about KRW 207.72 per share per year (typically in quarterly installments), a yield of roughly 2.8% at the current price. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For 002390.XKRX's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh 002390.XKRX's valuation and scores 10/100 on quality (lower-quality). It also yields about 2.8%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.